ACA
VRCA icon

Avoro Capital Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Avoro Capital Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-400,000
Closed -$29.2M – 40
2024
Q2 		$29.2M Hold
400,000
– – 0.39% 33
2024
Q1 		$23.7M Hold
400,000
– – 0.28% 43
2023
Q4 		$29.3M Buy
400,000
+104,594
+35% +$4.3M 0.4% 32
2023
Q3 		$11.5M Hold
295,406
– – 0.18% 38
2023
Q2 		$17M Buy
295,406
+30,406
+11% +$1.85M 0.23% 35
2023
Q1 		$17.2M Buy
+265,000
New +$16M 0.26% 32

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Avoro Capital Advisors's VRCA Position: Q3 2024 in Review

Avoro Capital Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2024, closing a stake of 400,000 shares — an estimated $29.2M sold.

Avoro Capital Advisors first reported a position in VRCA in Q1 2023 and held it in 6 quarters. The position peaked at $29.3M in Q4 2023. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

  • Avoro Capital Advisors reported no remaining Verrica Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Avoro Capital Advisors sold 400,000 Verrica Pharmaceuticals shares in Q3 2024, an estimated $29.2M.
  • Avoro Capital Advisors first reported a position in Verrica Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Avoro Capital Advisors's Verrica Pharmaceuticals position peaked at $29.3M in Q4 2023.
  • 79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on Avoro Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.